Matrix metalloproteinase inhibition impairs adipose tissue development in mice by Lijnen, Roger et al.
ISSN: 1524-4636 
Copyright © 2002 American Heart Association. All rights reserved. Print ISSN: 1079-5642. Online
7272 Greenville Avenue, Dallas, TX 72514
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association.
DOI: 10.1161/hq0302.104522 
 2002;22;374-379 Arterioscler Thromb Vasc Biol
H.R. Lijnen, E. Maquoi, L.B. Hansen, B. Van Hoef, L. Frederix and D. Collen 
 Mice
Matrix Metalloproteinase Inhibition Impairs Adipose Tissue Development in
 http://atvb.ahajournals.org/cgi/content/full/22/3/374
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints




Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://atvb.ahajournals.org/subscriptions/
Biology is online at 
Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular
 at SWETS SUBSCRIPTION SERVICE on February 12, 2010 atvb.ahajournals.orgDownloaded from 
Matrix Metalloproteinase Inhibition Impairs Adipose Tissue
Development in Mice
H.R. Lijnen, E. Maquoi, L.B. Hansen, B. Van Hoef, L. Frederix, D. Collen
Abstract—The effect of galardin, a broad-spectrum matrix metalloproteinase (MMP) inhibitor, was studied in mice kept
on a high fat diet (HFD). Five-week-old male wild-type mice were fed the HFD (42% fat) for up to 12 weeks and were
daily injected intraperitoneally with the inhibitor (100 mg/kg) or with vehicle. After 12 weeks of the HFD, the body
weights of both groups were comparable, but the weight of the isolated subcutaneous (SC) or gonadal (GON) fat
deposits was significantly lower in the inhibitor-treated group than in the control group (8811 versus 25166 mg,
respectively, for SC fat [P0.05]; 9024 versus 21730 mg, respectively, for GON fat [P0.02]). The number of
adipocytes was somewhat higher and the diameter was somewhat smaller (but not significantly) in adipose tissues of
the inhibitor-treated group. Adipose tissue of the inhibitor-treated mice contained more collagen than did that of the
vehicle-treated mice (Sirius red–stained area of 422.6% versus 224.4%, respectively, for SC fat [P0.05]; 215.1%
versus 4.70.92%, respectively, for GON fat [P0.01]); a distinct collagen-rich cap was formed around the
inhibitor-treated tissue. In situ zymography with casein- or gelatin-containing gels confirmed a reduced MMP activity
in SC and GON adipose tissues of inhibitor-treated mice. Thus, in this model, growth and development of adipose tissue
appears to be limited by the formation of a collagen-rich matrix cap around the inhibitor-treated tissue. These data
suggest a functional role for MMPs in the development of adipose tissue. (Arterioscler Thromb Vasc Biol. 2002;22:
374-379.)
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Obesity is a common disorder, and its related diseases,such as non–insulin-dependent diabetes mellitus, ath-
erosclerosis, and hypertension, are major causes of death and
disability in Western societies. The development of obesity is
associated with extensive modifications in adipose tissue
involving adipogenesis, angiogenesis, and extracellular ma-
trix (ECM) proteolysis.1 Proteolytic systems, eg, the plasmin-
ogen/plasmin (fibrinolytic) and matrix metalloproteinase
(MMP) system, contribute to tissue remodeling by degrada-
tion of the ECM and basement membrane components or by
activation of latent growth factors.2,3 Specific molecular
interactions between both proteolytic systems suggest that
they may cooperate in achieving ECM degradation.4 Plasmin-
ogen activator inhibitor-1 (PAI-1), the main physiological
plasminogen activator inhibitor, is highly expressed in adi-
pose tissue and may play a role in the development of
obesity.5–9 An MMP-2 (gelatinase A)–like gelatinolytic ac-
tivity was observed in conditioned medium of rat adipocytes
and may play a role in their organization into large multicel-
lular clusters.10 We have recently observed high expression of
MMP-2 in the adipose tissue of mice with nutritionally
induced obesity as well as in genetically obese mice. Its
localization in adipocytes has been suggested by immuno-
precipitation of the culture medium of isolated adipocytes, by
mRNA determination and by immunogold electron micros-
copy.11 Recently, it has been reported that the addition of
MMP inhibitors accelerated the accumulation of lipid during
differentiation of murine fibroblastic 3T3-L1 progenitor cells
and that differentiated adipocytes express and activate
MMP-2.12
To establish a potential role of the MMP system in adipose
tissue development, we have studied the effect of N-[2R-2-
(hydroxamido-carbonylmethyl)-4-methylpentanoyl]-L-
tryptophan methyl amide (galardin), a hydroxamate-based




Five-week-old male wild-type mice (mixed 75% C57/Bl6 and 25%
129SVj genetic background) were kept in microisolation cages on a
12-hour day-night cycle and fed a high fat diet (HFD) containing
42% fat (Harlan TD 88137). One group (n14) received daily
intraperitoneal injections of galardin at a dose of 100 mg/kg body wt
(sterile suspension of 20 mg/mL in 4% carboxymethylcellulose in
PBS, pH 7.3), and a control group (n14) received the vehicle
only.15 After 6 or 12 weeks, after they had fasted overnight, the mice
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were anesthetized by intraperitoneal injection of 60 mg/kg Nembutal
(Abbott Laboratories). Blood was collected with or without the
addition of trisodium citrate (final concentration 0.01 mol/L). Go-
nadal (GON) and subcutaneous (SC) fat pads were removed, and the
wet weight was determined. Portions were immediately frozen at
20°C for extraction or were prepared for histology. The SC fat pad
represented the adipose tissue overlying the posterior iliac crest and
was dissected from its attachment sites to the skin.
All animal experiments were approved by the local ethics com-
mittee and were performed in accordance with the guiding principles
of the American Physiological Society and the International Society
on Thrombosis and Hemostasis.16 Galardin was synthesized as
described.13 The final product was precipitated from a mixture of
H2O and ethyl acetate and was 98% pure, as evaluated by
high-performance liquid chromatography. The inhibitor was sus-
pended in 4% carboxymethylcellulose and sterilized before use.
Assays
Numbers of adipocytes (expressed as 106 per m2) in 15-m
frozen-cut adipose tissue sections, stained with hematoxylin-eosin
under standard conditions, and their mean diameters were deter-
mined by using a computer-assisted image analysis system (Axio-
plan 2, Zeiss).
For each animal, 3 to 5 areas in 4 different sections each were
analyzed. The data were first averaged per section and then per
animal. Staining of fibrillar collagen with Sirius red and of blood
vessels with a rabbit polyclonal antibody raised against rat throm-
bomodulin17 (a kind gift of Dr R. Jackman, Harvard University,
Boston, Mass) was performed on paraffin sections and quantified by
computer-assisted image analysis. Four to 9 sections were analyzed
per animal and then averaged.
Extraction of adipose tissue (250 mg/mL) was performed by
overnight incubation at 4°C on a tilting table in 10 mmol/L sodium
phosphate buffer, pH 7.2, containing 150 mmol/L NaCl, 1% Triton
X-100, 0.1% SDS, 0.5% sodium deoxycholate, and 0.2% NaN3.
After centrifugation, the protein concentration of the supernatant was
determined (BCA assay, Pierce). Zymographic analysis of gelatinase
activity was performed on 10% Tris-glycine gels with 0.1% gelatin,
and zymographic analysis of plasminogen activator (tissue-type
plasminogen activator [tPA] or urokinase-type plasminogen activa-
tor [uPA]) activity was performed on 12.5% acrylamide gels with
1% nonfat dry milk and 5 g/mL human plasminogen.18,19 The lysis
of the substrate gel (areaintensity) was quantified by image
analysis and expressed in arbitrary units (AU) of lysis per milligram
total protein in the extract.19
In situ zymography on cryosections of adipose tissue using casein-
or gelatin-containing gels was performed essentially as described.20
The substrate gel (0.5% agarose) contained 1.0 mg/mL resorufin-
labeled casein (Boehringer-Mannheim) or pig skin gelatin (Oregon
Green 488 conjugate, Molecular Probes Europe BV). Overlays were
analyzed by computer-assisted image analysis after incubation for 48
hours in a moist chamber at 37°C. Lysis is expressed as percentage
of the total section area.
Blood glucose concentrations were measured with the use of
Glucocard strips (Menarini Diagnostics). White blood cell, red blood
cell, platelet, hemoglobin, and hematocrit levels were determined by
using standard laboratory assays. PAI-1, tPA, uPA, plasminogen,
and 2-antiplasmin antigen levels were measured with specific
ELISAs.21,22
Data are reported as meanSEM, and statistical analysis was
performed by the nonparametric Student t test.
Results
Adipose Tissue Weight and Cellularity
During the experimental period, 5 of 14 animals died in the
control group compared with 2 of 14 animals in the inhibi-
tor-treated group. After 6 weeks on the HFD, the mice in the
inhibitor-treated group were not different from the mice in the
control group with respect to body weight (290.5 versus
290.9 g, respectively), weight gain (5.91.9 versus
7.41.3 g, respectively), SC fat mass (8315 versus 8927
mg, respectively), or GON fat mass (18045 versus 22041
mg, respectively). After 12 weeks on the HFD, body weight
and weight gain were also comparable in the inhibitor-treated
and vehicle-treated (control) mice (Table 1). However, un-
treated wild-type mice of the same genetic background kept
on the HFD for 12 weeks had a significantly higher body
weight (40.61.7 [meanSEM] g, n7; P0.01 versus
treated mice). After 12 weeks of the HFD, the SC and GON
fat pad weights were significantly lower in the inhibitor-
treated group (Table 1). However, the total fat mass was
lower than that in the untreated wild-type mice kept on the
HFD for 15 weeks (1.0 g in SC and GON territories).
Hematoxylin-eosin staining of adipose tissue sections did not
reveal differences in appearance (not shown). Analysis of the
cellularity of the fat deposits after 12 weeks of the HFD
revealed that the diameter of the adipocytes in tissue with
inhibitor was somewhat smaller than that in the tissue without
inhibitor but that the number of adipocytes per surface unit
was somewhat higher (both P0.06 for GON tissue, and both
P0.6 for SC tissue; Table 1).
Figure 1. Light-microscopic analysis of adipose tissue. GON adi-
pose tissue derived from mice treated with vehicle (a and b) or with
inhibitor (c and d) for 12 weeks was stained with an antibody
against thrombomodulin (a and c) or with Sirius red (b and d).
TABLE 1. Effect of MMP Inhibition on Body Weight Gain and
on Adipose Tissue Weight and Cellularity in Mice Kept on HFD
for 12 Weeks
No Inhibitor Inhibitor
Body weight, g 322.7 332.8
Weight gain, g 111.8 121.4
SC fat, mg 25166 8811*







Values are meanSEM of 5 or 6 animals in control or inhibitor groups.
*P0.05 and †P0.02 vs corresponding group without inhibitor.
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Staining of GON adipose tissue sections with an antibody
against thrombomodulin (Figure 1a and 1c) revealed a higher
blood vessel density in the inhibitor-treated animals com-
pared with the control animals (stained area was 4.90.43%
versus 2.80.26% of the total area, respectively; P0.038).
Staining of adipose tissue sections for collagen with Sirius
red (Figure 1b and 1d) revealed the presence of more collagen
throughout the inhibitor-treated samples compared with the
control samples (stained area was 422.6% versus 224.4%,
respectively, of the total area [P0.05] for SC tissue, with
corresponding values of 215.1% versus 4.70.92%
[P0.01] for GON tissue). In the inhibitor-treated samples,
collagen was much more abundant at the borders of the
adipose tissue, forming a cap around the tissue. Similar
observations were made for SC and GON adipose tissue. Red
to orange birefringent collagen was more pronounced in
inhibitor samples than in control samples, indicating more
collagen disorganization in the control samples (not shown).
Blood and Adipose Tissue Parameters
Glucose levels were comparable in the control and inhibitor-
treated groups at 12 weeks, and plasma plasminogen and
2-antiplasmin levels were normal in both groups. As ob-
served previously with this HFD,9 plasma PAI-1 levels were
strongly elevated in both groups (normal levels on regular
chow are 1 to 3 ng/mL); however, differences between
control and inhibitor-treated groups were statistically not
significant. Other hemostatic parameters, including white
blood cell, red blood cell, and platelet counts and hemoglobin
and hematocrit levels, were not different (Table 2). Similar
data were obtained in the inhibitor- and vehicle-treated
groups after 6 weeks of HFD (not shown).
In extracts of SC or GON adipose tissue, PAI-1, tPA, and
uPA antigen levels were comparable in the control and
inhibitor-treated groups (Table 3). Zymography of extracts on
casein-containing gels confirmed the presence of tPA and
uPA activity at comparable levels (Figure 2A). Zymography
TABLE 2. Effect of MMP Inhibition on Metabolic and
Hematologic Parameters in Mice Kept on HFD for 12 Weeks
No Inhibitor Inhibitor
Glucose, mg/dL 12412 9810
PAI-1, ng/mL 9.70.60 269.9
Plasminogen, g/mL 993.9 855.8
2-Antiplasmin, g/mL 12012 939.3
WBCs, 109/L 3.10.3 3.20.2
RBCs, 1012/L 6.90.2 6.00.6
Hemoglobin, g/dL 120.6 110.9
Hematocrit, % 311.1 273.0
Platelets, 109/L 70066 66053
WBC indicates white blood cell; RBC, red blood cell. Values are meanSEM
of 5 or 6 animals in control or inhibitor groups.
TABLE 3. MMP and Fibrinolytic System Components in Adipose Tissue of Mice
Kept on HFD for 12 Weeks
No Inhibitor Inhibitor
SC GON SC GON
PAI-1 antigen,* ng/mg 1.10.10 1.10.41 1.70.87 0.520.14
tPA antigen,* ng/mg 0.720.20 1.50.54 0.570.06 1.00.07
tPA activity,† AU/mg 132.4 285.2 133.1 244.6
uPA antigen,* ng/mg 4.90.69 8.21.2 2.50.51 4.50.82
uPA activity,† AU/mg 9213 15012 9310 14086
70-kDa proMMP-2,† AU/mg 4911 125.4 3720 132.5
65-kDa proMMP-2,† AU/mg 16023 5211 30087 678.5
61-kDa MMP-2,† AU/mg 935.0 133.8 12011 297.1
58-kDa MMP-2,† AU/mg 6913 1.20.8 9926 136.9
Values are meanSEM of 5 or 6 animals.
*Antigen levels are expressed as nanograms per milligram protein in the extract.
†Activity levels are expressed as AU of lysis per milligram protein in the extracts.
Figure 2. Zymographic analysis of adipose tissue. Extracts of
SC (lanes 1 and 2) or GON (lanes 3 and 4) adipose tissue
obtained from mice kept on HFD for 12 weeks without (lanes 1
and 3) or with (lanes 2 and 4) inhibitor administration were
applied to casein-containing (A) or gelatin-containing (B) gels.
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on gelatin-containing gels revealed the presence of 70- and
65-kDa proMMP-2 and of 61- and 58-kDa active MMP-2
species, whereas MMP-9 levels were not detectable (Figure
2B). Addition to the incubation buffer of EDTA (final
concentration 20 mmol/L) or galardin (final concentration
0.5 mmol/L) totally abolished the lysis zones on the gel,
confirming their MMP nature as well as the inhibitory
activity of galardin. The addition of galardin (final concen-
tration 0.05 mmol/L) to extracts of the control group did not
abolish the detected gelatinolytic activity, suggesting that the
inhibitor dissociates during electrophoresis (data not shown).
The levels of the different molecular species of MMP-2 were
somewhat lower in GON than in SC adipose tissue but were
comparable with or without inhibitor treatment (Table 3). The
total MMP-2 levels at 12 weeks (all 4 forms combined) were
not significantly different in the absence or the presence of
the inhibitor, either in the SC tissue (36041 versus
550120 AU/mg, respectively; P0.43) or in the GON
tissue (7919 versus 12015 AU/mg, respectively;
P0.18). Also, the ratio of active (61 plus 58 kDa) versus
latent (70 plus 65 kDa) MMP-2 was comparable in the
absence or presence of the inhibitor for the SC tissue (0.78
versus 0.67, respectively) but somewhat different for the
GON tissue (0.22 versus 0.53, respectively). Very similar
data were obtained for the fibrinolytic parameters and gela-
tinase levels in adipose tissue extracts of the inhibitor- and
vehicle-treated groups after 6 weeks of HFD (not shown).
In situ zymography with casein- or gelatin-containing gels
on cryosections of SC or GON adipose tissue confirmed a
lower MMP activity in the tissue of inhibitor-treated animals
(Table 4); these differences were statistically significant for
the SC tissue (both P0.05) but not for the GON tissue
(P0.12 or P0.79, respectively). The addition of a mixture
of EDTA (final concentration 25 mmol/L) and 1,10-
phenanthroline (final concentration 5 mmol/L) to the agarose
gel resulted in inhibition of 60% to 85% of the lytic activity
in the different experiments (not shown).
Discussion
Fat pad formation, the concerted assembly of adipose, vas-
cular, and nervous tissues, is a complex process. Formation of
adipose tissue, the major cellular component, involves com-
mitment of mesodermal stem cells to a preadipocyte lineage
and differentiation of preadipocytes into adipocytes.10 Differ-
entiation is associated with an increased secretion of base-
ment membrane components such as laminin, proteoglycans,
and type IV collagen and decreased secretion of fibrillar type
I collagen. The organization of adipocytes in spherical
clusters requires accumulation in the extracellular space of
sufficient basement membrane components to generate a
surrounding basal lamina. ECM components are indeed
synthesized and degraded during adipocyte differentia-
tion23–25 and may modulate it.26 MMP-2 was suggested to
play a role in adipocyte clustering, inasmuch as its inhibition
prevented this process.10 Furthermore, MMP-2 is highly
expressed in the adipose tissue of obese mice.11 It has also
been reported that MMP-2 increases and that tissue inhibitor
of MMPs type 1 (TIMP-1) decreases during adipocyte dif-
ferentiation.10,27 MMP-2 and MMP-9 expression and secre-
tion have also recently been demonstrated in human adipose
tissue.28
To test the hypothesis that MMP-mediated matrix degra-
dation plays a role in the development of adipose tissue, we
have studied the effect of galardin, a broad-spectrum MMP
inhibitor, in a mouse model of nutritionally induced obesity.
Galardin is a peptide-based zinc-chelating hydroxamate that
inhibits several MMPs, including gelatinase A (MMP-2),
gelatinase B (MMP-9), interstitial collagenase (MMP-1),
neutrophil collagenase (MMP-8), and stromelysin-1 (MMP-
3).13,14 In the present study, 5-week-old male wild-type mice
were kept on the HFD for up to 12 weeks, whereas galardin
was administered by daily intraperitoneal injections.
To monitor the effects of daily intraperitoneal injections of
inhibitor on body weight gain, a control group was included
that received daily injections of the vehicle (4% carboxym-
ethylcellulose). Body weight gain during 12 weeks was
comparable in the inhibitor- and vehicle-treated groups.
Compared with wild-type mice of the same genetic back-
ground kept on the HFD for 12 weeks without injections, the
body weight and the SC and GON fat mass in the present
study were lower. This may be due to higher plasma PAI-1
levels observed in the present study for inhibitor-injected
mice on the HFD compared with wild-type mice on the HFD
without injections (10 to 25 ng/mL versus 5 to 10 ng/mL,
respectively). This increase may be due to a combined effect
of the HFD and of the carboxymethylcellulose injections and
may contribute to the low body weight gain in all groups. It
has indeed been previously shown that the HFD induces
elevated PAI-1 levels and that these are associated with lower
body weight gain during HFD feeding.9 Alternatively, stress
effects due to the daily injections and, possibly, loss of
appetite may play a role. As discussed above, we have taken
care to have an identical injection scheme in all experimental
groups.
In the control group but not in the inhibitor group, the
weight of the SC fat pad increased between 6 and 12 weeks
of the HFD; in contrast, the weight of the GON fat pad was
not further increased in the control group and even decreased
in the inhibitor group. This suggests a differential effect of
prolonged galardin administration on the development of SC
and GON adipose tissue, which may partly be due to lower
collagen content in the GON tissue but may also be due to a
differential pattern of MMP expression. Comparison of
mRNA expression between GON and SC fat from obese mice
indeed revealed depot-specific expression patterns.29 At pres-
ent, we cannot exclude the possibility that the broad-spectrum
TABLE 4. Effect of MMP Inhibition on Gelatinolytic or
Caseinolytic Activity in Adipose Tissue, as Measured by In
Situ Zymography
Lysis, % of Section Area
Gelatin Casein
SC
No inhibitor 262.6 242.3
Inhibitor 133.7* 133.7*
GON
No inhibitor 193.3 201.0
Inhibitor 153.5 143.1
Values are meanSEM of 5 or 6 animals.
*P0.05 vs control without inhibitor.
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inhibitor galardin affects other MMPs in both types of
adipose tissue. However, the overall effect of the inhibitor is
a reduction of fat mass.
Overall, the inhibitor appeared to be well tolerated, which
is in agreement with several previous studies in which no
general toxicity of systemic galardin administration was
observed.15,30–34 In all these models, significant biological
activity of galardin was reported, most likely as a result of
MMP inhibition. We demonstrated by in situ zymography
reduced gelatinolytic activity at the level of the inhibitor-
treated adipose tissue, indicating that MMP-2 and/or MMP-9
is inhibited. Because galardin is a broad-spectrum inhibitor, it
cannot be excluded that other MMPs are also inhibited, as
suggested by the finding that in situ caseinolytic activity is
also reduced (Table 4). In addition, SC and GON adipose
tissues from inhibitor-treated animals contained more colla-
gen than did those tissues from vehicle-treated mice. In an
experimental balloon angioplasty injury model in the rabbit, it
has previously been observed that galardin reduces collagen
synthesis and degradation.32 It is not clear whether in the
present study in adipose tissue the inhibitor also had an effect
on collagen synthesis. However, it was apparent that collagen
was much more abundant at the borders of the adipose tissue
of inhibitor-treated mice, forming a cap surrounding the
tissue. It is also possible that in the vehicle-treated adipose
tissue, other cell types are more abundantly present (eg, more
stromal-vascular cells), which may contribute to larger fat
pads. A similar observation with collagen has previously been
reported in tumor tissues of mice treated with an MMP
inhibitor.35 By reducing the rate of collagen degradation and
simultaneously stimulating collagen biosynthesis, the body
may be able to encapsulate the invading tumor in collagen
structures.36 Studies with MMP inhibitors in tumor models
have suggested that inhibition of growth could occur by the
development of fibrotic tissue around the tumor, thereby
preventing invasive growth, or by the inhibition of angiogen-
esis.35 Hydroxamate-based MMP inhibitors have been shown
to cause significant inhibition of SC rat prostate tumors in
nude mice, but no obvious effect on tumor angiogenesis has
been observed.37
MMPs may indeed be involved in direct matrix degrada-
tion, but they may also be involved in angiogenesis. Galardin
has previously been shown to reduce the number and area of
new blood vessels in rat corneas implanted with pellets
containing extracts of a malignant carcinoma.30 However, our
in vivo data indicate that MMP inhibition with galardin
results in a higher blood vessel density in adipose tissue. This
may be explained by the fact that the total mass of the adipose
tissue is lower in the inhibitor-treated animals, whereby a
relatively comparable angiogenesis in inhibitor-treated and
control groups would be perceived as a higher blood vessel
density in the more compact inhibitor-treated tissue. Lund et
al15 have reported that daily administration of galardin to
mice results in the enhanced expression of mRNAs for
stromelysin-1, gelatinase B, and collagenease-3 in keratino-
cytes. In the present study, we did not see an enhanced
expression of MMP-2 or MMP-9 in adipose tissue, at least
not at the protein level, after the administration of galardin.
However, gelatin zymography with extracts does not allow us
to quantify active MMP, as it is presented in the tissue,
because of dissociation from the inhibitor, but it did allow us
to demonstrate that total amounts of gelatinases were com-
parable in the inhibitor-treated and control groups.
Recently, a regulatory role of MMP-3 (stromelysin-1) has
been suggested in adipogenesis during mammary gland invo-
lution in mice; mice with MMP-3 deficiency or overexpres-
sion of TIMP-1 indeed showed accelerated differentiation
and hypertrophy of adipocytes. In addition, galardin acceler-
ated lipid accumulation during in vitro differentiation of
fibroblastic 3T3-L1 progenitor cells. These data thus suggest
an inhibitory effect of MMPs (MMP-3) on adipocyte metab-
olism and differentiation.12 This was explained by preventing
the assembly of basement membrane, possibly as a result of
the MMP-3–mediated cleavage of entactin.12 We observed a
decrease in adipose tissue weight in the inhibitor-treated
group. This may be due to an effect of MMP inhibition on
other processes contributing to adipogenesis. It is also possi-
ble that the inhibitory effect of MMP-3 on adipogenesis is
seen only in processes that occur relatively rapidly, such as
mammary gland involution.
In view of the previous observations that PAI-1 is highly
expressed in adipose tissue5–9 and of the potential interactions
between the fibrinolytic and MMP systems,3,4 we have also
determined fibrinolytic parameters in extracts of adipose
tissue. We did not observe significant differences in PAI-1
antigen and in tPA or uPA antigen and activity levels.
Taken together, our findings of reduced collagen degrada-
tion on administration of the broad-spectrum MMP inhibitor
indicate that the formation of a collagen-rich matrix cap
impairs adipose tissue growth, suggesting a functional role
for MMPs. It will be interesting to investigate whether other
orally administered and eventually more specific MMP in-
hibitors will have a similar effect on adipose tissue develop-
ment in vivo.
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